Effect of functional power training on the walking ability of children with spastic cerebral palsy in the age of 4 to 10 years

Completed

Conditions: 10042258
'Spastic Cerebral Palsy'
'spastic child'

Registration Number: NL-OMON40459

Lead Sponsor: Amsterdam Rehabilitation Research Center | Reade

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 20

Inclusion Criteria

Children with diagnosis of predominantly spastic type of Cerebral Palsy, aged 4-10 years, being ambulant without assistive devices (GMFCS level I and II).
Parents and/or the children want to improve the walking ability of the child.
The children are able to follow instructions to perform the exercises and tests.

Exclusion Criteria

Treatment with botulinum toxin A in lower limb or serial casting of lower limb less than 6 months before the MegaPower training starts.
Treatment of selective dorsal rhizotomie less than 12 months before the MegaPower training starts.
Walking is not (yet) the preferred way to move around.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary study parameters;<br /><br>The objective primary outcome to measure the effect of the MegaPower training<br /><br>is the Muscle Power Sprint Test (MPST). The Goal Attainment Scaling (GAS) is<br /><br>the subjective, reported by the parents, primary outcome.<br /><br>The MPST is a 6 times 15 meter sprint test. Between the 6 sprints is a 10 sec<br /><br>break in which the child can turn and be ready for the next sprint. The time<br /><br>used for each sprint is measured with 0.01 second precision. Together with body<br /><br>height and weight power will be calculated and expressed in Watts. The MPST<br /><br>measures the anaerobic capacity of the child expressed in mean power and peak<br /><br>power. The reliability of the test is good (ICC=0.97).<br /><br>With GAS the extent of reaching the treatment goal will be measured. GAS is a<br /><br>sensitive, individual, evaluative measurement which describes the change of<br /><br>individuals or groups after treatment (ICC = 0.86).</p><br>

Secondary Outcome Measures